0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Leads from the MMWR

JAMA. 1986;256(1):20-25. doi:10.1001/jama.1986.03380010024007.
Text Size: A A A
Published online

Extract

The AIDS virus has been variously termed human T-lymphotropic virus type III (HTLV-III), lymphadenopathy-associated virus (LAV), AIDS-associated retrovirus (ARV), or human immunodeficiency virus (HIV). The designation human immunodeficiency virus (HIV) has recently been proposed by a subcommittee of the International Committee for the Taxonomy of Viruses as the appropriate name for the retrovirus that has been implicated as the causative agent of AIDS.4
The following persons served on the review panel: DS Burke, MD, RR Redfield, MD, Walter Reed Army Institute of Research, Washington, DC; J Chin, MD, State Epidemiologist, California Department of Health Services; LZ Cooper, MD, St Luke's-Roosevelt Hospital Center, New York City; JP Davis, MD, State Epidemiologist, Wisconsin Division of Health; MA Fischl, MD, University of Miami School of Medicine, Miami, Florida; G Friedland, MD, Albert Einstein College of Medicine, New York City; MA Johnson, MD, DI Abrams, MD, San Francisco General Hospital; D Mildvan, MD, Beth Israel Medical Center, New York City; CU Tuazon, MD, George Washington University School of Medicine, Washington, DC; RW Price, MD, Memorial Sloan-Kettering Cancer Center, New York City; C Konigsberg, MD, Broward County Public Health Unit, Fort Lauderdale, Florida; MS Gottlieb, MD, University of California—Los Angeles Medical Center; representatives of the National Institute of Allergy and Infectious Diseases, National Cancer Institute, National Institutes of Health; Center for Infectious Diseases, the CDC.
This subgroup includes patients with one or more of the specified infectious diseases listed whose clinical presentation fulfills the definition of AIDS as used by CDC for national reporting.
This subgroup includes those patients with one or more of the specified cancers listed whose clinical presentation fulfills the definition of AIDS as used by CDC for national reporting.
Gallo RC, Salahuddin SZ, Popovic M, et al:  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS . Science 1984;224:500-503.
Link to Article[[XSLOpenURL/10.1126/science.6200936]]
Barre-Sinoussi F, Chermann JC, Rey F, et al:  Isolation of a T lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) . Science 1983;220:868-871.
Link to Article[[XSLOpenURL/10.1126/science.6189183]]
Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JMro LS:  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS . Science 1984;225:840-842.
Link to Article[[XSLOpenURL/10.1126/science.6206563]]
Coffin J, Haase A, Levy JA, et al:  Human immunodeficiency viruses (Letter) . Science 1986; 232:697.
Link to Article[[XSLOpenURL/10.1126/science.3008335]]
CDC:  Revision of the case definition of acquired immunodeficiency syndrome for national reporting—United States . MMWR 1985;34:373-375.
Haverkos HW, Gottlieb MS, Killen JY, Edelman R:  Classification of HTLV-III/LAV-related diseases (Letter) . J Infect Dis 1985;152:1095.
Link to Article[[XSLOpenURL/10.1093/infdis/152.5.1095]]
Redfield RR, Wright DC, Tramont EC:  The Walter Reed staging classification for HTLV-III/LAV infection . N Engl J Med 1986;314:131-132.
Link to Article[[XSLOpenURL/10.1056/NEJM198601093140232]]
CDC:  Antibodies to a retrovirus etiologically associated with acquired immunodeficiency syndrome (AIDS) in populations with increased incidences of the syndrome . MMWR 1984;33:377-379.
CDC:  Update: Public Health Service Workshop on Human T-Lymphotropic Virus Type III Antibody Testing—United States . MMWR 1985;34:477-478.
CDC:  Additional recommendations to reduce sexual and drug abuse case-related transmission of human T-lymphotropic-associated virus . MMWR 1986;35:152-155.
Selik RM, Haverkos HW, Curran JW:  Acquired immune deficiency syndrome (AIDS) trends in the United States, 1978-1982 . Am J Med 1984;76:493-500.
Link to Article[[XSLOpenURL/10.1016/0002-9343(84)90669-7]]
Sarngadharan MG, Popovic M, Bruch L, Schupbach J, Gallo RC:  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS . Science 1984; 224:506-508.
Link to Article[[XSLOpenURL/10.1126/science.6324345]]
Safai B, Sarngadharan MG, Groopman JE, et al:  Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome . Lancet 1984;I:1438-1440
Link to Article[[XSLOpenURL/10.1016/S0140-6736(84)91933-0]]
Laurence J, Brun-Vezinet F, Schutzer SE, et al:  Lymphadenopathy associated viral antibody in AIDS. Immune correlations and definition of a carrier state . N Engl J Med 1984;311:1269-1273.
Link to Article[[XSLOpenURL/10.1056/NEJM198411153112001]]
Ho DD, Sarngadharan MG, Resnick L, Dimarzo-Veronese F, Rota TR, Hirsch MS:  Primary human T-lymphotropic virus type III infection . Ann Intern Med 1985;103:880-883.
Link to Article[[XSLOpenURL/10.7326/0003-4819-103-6-880]]
Cooper DA, Gold J, Maclean P, et al:  Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion . Lancet 1985;1:537-540.
Link to Article[[XSLOpenURL/10.1016/S0140-6736(85)91205-X]]
CDC:  Tetracycline-resistant Neisseria gonorrhoeae—Georgia, Pennsylvania, New Hampshire . MMWR 1985;34:563-564, 569-570.
Ashford WA, Potts DW, Adams HJU, et al:  Spectinomycin-resistant penicillinase-producing Neisseria gonorrhoeae . Lancet 1981;11:1035-1037.
Link to Article[[XSLOpenURL/10.1016/S0140-6736(81)91227-7]]
Piziak MV, Woodbury C, Berliner D, et al:  Resistance trends of Neisseria gonorrhoeae in the Republic of Korea . Antimicrob Agents Chemother 1984;25:7-9.
Link to Article[[XSLOpenURL/10.1128/AAC.25.1.7]]
Rice RJ, Biddle JW, Jean-Louis YA, DeWitt WE, Blount JH, Morse SA:  Chromosomally mediated resistance in Neisseria gonorrhoeae in the United States: results of surveillance and reporting 1983-1984 . J Infect Dis 1986;153:340-345.
Link to Article[[XSLOpenURL/10.1093/infdis/153.2.340]]
CDC:  1985 STD treatment guidelines . MMWR 1985;34( (suppl 4S) ):75S-108S.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();